Synthesis and evaluation of 7α-(3-[(18)F]fluoropropyl) estradiol.

[1]  Shun Kobayashi,et al.  Synthesis and bioassay of a boron-dipyrromethene derivative of estradiol for fluorescence imaging in vivo , 2012, Steroids.

[2]  V. Wilson,et al.  Assessment of a robust model protocol with accelerated throughput for a human recombinant full length estrogen receptor-alpha binding assay: protocol optimization and intralaboratory assay performance as initial steps towards validation. , 2010, Reproductive toxicology.

[3]  J. E. Lier,et al.  18F-labelling of A-ring substituted 16α-fluoro-estradiols as potential radiopharmaceuticals for PET imaging , 2009, Steroids.

[4]  Michael J. Welch,et al.  Synthesis of an Estrogen Receptor β-Selective Radioligand: 5-[18F]Fluoro-(2R*,3S*)-2,3-bis(4-hydroxyphenyl)pentanenitrile and Comparison of in Vivo Distribution with 16α-[18F]Fluoro-17β-estradiol , 2005 .

[5]  Yann Seimbille,et al.  18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals , 2002, Steroids.

[6]  G. Slegers,et al.  Radiolabeled estradiol derivatives to predict response to hormonal treatment in breast cancer: a review , 2000, European Journal of Nuclear Medicine.

[7]  H Fang,et al.  The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  J. Katzenellenbogen,et al.  Synthesis and Binding Affinities of Novel Re-Containing 7alpha-Substituted Estradiol Complexes: Models for Breast Cancer Imaging Agents. , 1999, The Journal of organic chemistry.

[9]  D. Mankoff,et al.  Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). , 1997, Nuclear medicine and biology.

[10]  John A. Katzenellenbogen,et al.  The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site , 1997, Steroids.

[11]  J E Mortimer,et al.  Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  M. Welch,et al.  16β-((18F)Fluoro)estrogens: Systematic Investigation of a New Series of Fluorine-18-Labeled Estrogens as Potential Imaging Agents for Estrogen-Receptor-Positive Breast Tumors. , 1993 .

[13]  M. Welch,et al.  Titration of the in vivo uptake of 16 alpha-[18F]fluoroestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding radiopharmaceutical development. , 1993, Nuclear medicine and biology.

[14]  M. Welch,et al.  16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors. , 1993, Journal of medicinal chemistry.

[15]  Scott R. Wilson,et al.  A synthesis of 7α-substituted estradiols: synthesis and biological evaluation of a 7α-pentyl-substituted BODIPY fluorescent conjugate and a fluorine-18-labeled 7α-pentylestradiol analog , 1993, Steroids.

[16]  M. Mintun,et al.  Positron Tomographic Assessment of 16α-[18F] Fluoro-17β-Estradiol Uptake in Metastatic Breast Carcinoma , 1991 .

[17]  C. Labrie,et al.  Synthesis and biological activity of new halo-steroidal antiestrogens. , 1991, Journal of medicinal chemistry.

[18]  J. V. van Lier,et al.  Synthesis and structure-affinity of a series of 7 alpha-undecylestradiol derivatives: a potential vector for therapy and imaging of estrogen-receptor-positive cancers. , 1990, Journal of medicinal chemistry.

[19]  A. Wakeling,et al.  Novel steroidal pure antiestrogens , 1989, Steroids.

[20]  M. Mintun,et al.  Breast cancer: PET imaging of estrogen receptors. , 1988, Radiology.

[21]  J. Katzenellenbogen,et al.  Estrogen receptor binding tolerance of 16α-substituted estradiol derivatives , 1988, Steroids.

[22]  G M Clark,et al.  Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. J. Roth,et al.  Synthese und Eigenschaften fluoreszierender Estradiol‐Derivate , 1986 .

[24]  B. Rasmussen,et al.  BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES , 1985, The Lancet.

[25]  M. Welch,et al.  Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  A. Giuliano,et al.  Breast cancers: estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response. , 1984, The Journal of surgical research.

[27]  B. Furr,et al.  The pharmacology and clinical uses of tamoxifen. , 1984, Pharmacology & therapeutics.

[28]  R Bucourt,et al.  New biospecific adsorbents for the purification of estradiol receptor. , 1978, The Journal of biological chemistry.

[29]  E. Baulieu,et al.  Estrogens and antiestrogens. , 1972, Gynecologic investigation.